Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States

PURPOSE: Based on available phase III trial data, we performed a cost-effectiveness analysis of different treatment strategies that can be used in patients with newly diagnosed HER2-positive metastatic breast cancer (mBC). PATIENTS AND METHODS: We constructed a Markov model to assess the cost-effect...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Diaby, Vakaramoko, Adunlin, Georges, Ali, Askal A., Zeichner, Simon B., de Lima Lopes, Gilberto, Kohn, Christine G., Montero, Alberto J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5329168/
https://ncbi.nlm.nih.gov/pubmed/27654970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-016-3978-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados